SenzaGen

SenzaGen Employees

The The number of employees of SenzaGen (SENZA.ST) as of Nov 7, 2026 is 16. In the previous year, The number of employees was 16.00 — a change of 0.00% (lower).

Employees

16

YoY

0.00%

Last updated:

In 2025, SenzaGen employed 16 people, a 0.00% change from the 16.00 number of employees in the previous year.

The SenzaGen Employees history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Employees
Date
Employees
Jan 1, 2018
16.00 SEK
Jan 1, 2019
16.00 SEK
Jan 1, 2020
16.00 SEK
Jan 1, 2021
16.00 SEK
Jan 1, 2022
16.00 SEK
Jan 1, 2023
16.00 SEK
Jan 1, 2024
16.00 SEK
Jan 1, 2025
16.00 SEK
The SenzaGen Employees history
YEAREmployeesYoY
160.00%
160.00%
160.00%
160.00%
160.00%
160.00%
160.00%
160.00%
160.00%
160.00%
160.00%
16—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SenzaGen Stock analysis

What does SenzaGen do? SenzaGen AB is a Swedish biotechnology company that specializes in the development and marketing of innovative and reliable tests for assessing allergenicity. Founded in 2010 by leading experts from the academic and industry sectors, the company has become a significant player in the field of toxicology. Current methods for assessing allergenicity, such as asthma, eczema, and allergic reactions, are often inaccurate and require the use of animals, which is ethically questionable and expensive. SenzaGen AB has developed a wide range of tests based on biomolecular technologies that use human cells to assess the allergenic reactivity of chemicals and products. These tests are accurate, cost-effective, and meet the current requirements of regulatory authorities and the industry. The company is headquartered in Lund, Sweden, and currently employs about 20 people. SenzaGen AB is a leader in the development of in vitro methods for evaluating allergenicity and utilizes various platform technologies such as gene expression and proteomics analysis, as well as the use of immune cells and keratinocytes. SenzaGen AB's Microarray technology platform, based on DNA-based tests, has been recognized by the European Chemicals Agency (ECHA) as suitable for assessing allergenic reactivity. The company has also partnered with the US biotechnology company In vitro International (IVI) to distribute its allergen tests in the North American market. SenzaGen AB has developed a wide range of products that can be used in various sectors such as cosmetics, food, chemicals, and pharmaceuticals. AllergoDx™ is a test system used by the pharmaceutical and chemical industries to determine the allergenic reactivity of chemicals. GARD™ (Genomic Allergen Rapid Detection) is a rapid test used in the cosmetics and food industries to determine the allergenic reactivity of new products and avoid costly animal testing. GARDskin™ is a skin test used to determine the reactivity of substances that come into contact with the skin, primarily in the chemicals and pharmaceutical industries. Other products in the company's pipeline include GARDpotency™ and GARDair™, which are intended for assessing allergic reactions in industrial and occupational environments. SenzaGen AB has experienced significant growth in recent years and plans to expand its product range and strengthen its market position. The company's business model is based on selling tests and services to chemical, pharmaceutical, food, and cosmetic companies worldwide. Through its innovative technologies and willingness to collaborate with customers, the company has taken a leadership role in toxicology. SenzaGen AB is committed to an ethical and responsible corporate philosophy focused on sustainability and environmental protection. The company has clear goals to meet the growing demand for reliable and ethical testing methods to minimize the impact of chemicals on humans and the environment. SenzaGen is one of the most popular companies on Eulerpool.

Employees Details

Examining SenzaGen's Employee Base

SenzaGen's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding SenzaGen's operational capacity and future potential.

Year-to-Year Comparison

Assessing SenzaGen's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

SenzaGen's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in SenzaGen’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about SenzaGen stock

The number of employees of SenzaGen is 16 in 2025.

The number of employees of SenzaGen changed from 16.00 to 16, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of employees SenzaGen since 2006 – with annual values, charts, and detailed analysis.

The number of employees describes the number of people directly employed by the company.

The number of employees's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The number of employees's SenzaGen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — SenzaGen

All Key Metrics — SenzaGen